High-risk cytogenetics and persistent minimal residual disease by multiparameter flow cytometry predict unsustained complete response after autologous stem cell transplantation in multiple myelomaBruno Paiva, Jesús F. San Miguel, Norma C. Gutiérrez et al.|Blood|2011Cited by 304
A prospective PETHEMA study of tandem autologous transplantation versus autograft followed by reduced-intensity conditioning allogeneic transplantation in newly diagnosed multiple myelomaLaura Rosiñol, Joan Bladé, Josè Antonio Pérez-Simón et al.|Blood|2008Cited by 264
Bortezomib, lenalidomide, and dexamethasone as induction therapy prior to autologous transplant in multiple myelomaLaura Rosiñol, Joan Bladé, Albert Oriol et al.|Blood|2019Cited by 218
Competition between clonal plasma cells and normal cells for potentially overlapping bone marrow niches is associated with a progressively altered cellular distribution in MGUS vs myelomaBruno Paiva, Martín Pérez‐Andrés, María‐Belén Vídriales et al.|Leukemia|2011Cited by 91
Thalidomide / Dexamethasone (TD) Vs. Bortezomib (Velcade)a/Thalidomide / Dexamethasone (VTD) Vs. VBMCP/VBAD/Velcadea as Induction Regimens Prior Autologous Stem Cell Transplantation (ASCT) in Multiple Myeloma (MM): Results of a Phase III PETHEMA/GEM Trial.Laura Rosiñol, Joan Bladé, M. Teresa Cibeira et al.|Blood|2009Cited by 45